{"drugs":["Indocin","Indomethacin Sodium"],"mono":{"0":{"id":"922386-s-0","title":"Generic Names","mono":"Indomethacin Sodium"},"1":{"id":"922386-s-1","title":"Dosing and Indications","sub":{"1":{"id":"922386-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Patent ductus arteriosus:<\/b> younger than 48 hours: initial, 0.2 mg\/kg IV, followed by 0.1 mg\/kg IV at 12 to 24 hour intervals for the second and third doses<\/li><li><b>Patent ductus arteriosus:<\/b> 2 to 7 days old: initial, 0.2 mg\/kg IV, followed by 0.2 mg\/kg IV at 12 to 24 hour intervals for the second and third doses<\/li><li><b>Patent ductus arteriosus:<\/b> older than 7 days, initial, 0.2 mg\/kg IV, followed by 0.25 mg\/kg IV at 12 to 24 hour intervals for the second and third doses<\/li><\/ul>"},"2":{"id":"922386-s-1-6","title":"Dose Adjustments","mono":"<b>renal impairment:<\/b> anuria or marked oliguria (urinary output less than 0.6 mL\/kg\/hr), hold dose until renal function returns to normal "},"3":{"id":"922386-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Patent ductus arteriosus<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Cholecystitis<\/li><li>Hypotension<\/li><li>Pain<\/li><li>Ureteric colic<\/li><\/ul>"}}},"3":{"id":"922386-s-3","title":"Contraindications\/Warnings","sub":[{"id":"922386-s-3-9","title":"Contraindications","mono":"<ul><li>bleeding; especially active intracranial hemorrhage or gastrointestinal bleeding<\/li><li>coagulation defects<\/li><li>congenital heart disease in which patency of the ductus arteriosus is necessary for adequate pulmonary or systemic blood flow (ie, pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta)<\/li><li>infection, proven or suspected and untreated<\/li><li>necrotizing enterocolitis, known or suspected<\/li><li>renal impairment, significant<\/li><li>thrombocytopenia<\/li><\/ul>"},{"id":"922386-s-3-10","title":"Precautions","mono":"<ul><li>hepatic reactions, severe, have been reported in adults<\/li><li>gastrointestinal bleeding (major and minor) has been reported<\/li><li>infection; drug may mask signs or symptoms<\/li><li>platelet aggregation may be inhibited; increased risk of intraventricular bleeding; monitoring recommended<\/li><li>renal effects have been reported including acute renal failure; increased risk with other conditions which may adversely affect renal function (ie, congestive heart failure, sepsis, volume depletion, hepatic dysfunction) or concomitant use of nephrotoxic drugs; if significant suppression of urine volume occurs, delay subsequent doses until urine output normalizes<\/li><li>suppression of water excretion to a greater extent than sodium excretion may occur; may result in hyponatremia; monitoring recommended<\/li><li>tissue irritation may occur; avoid extravascular injection or leakage<\/li><\/ul>"},{"id":"922386-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Indomethacin: C (1st trimester), C (2nd trimester), D (3rd trimester) (FDA)<\/li><li>Indomethacin: C (AUS)<\/li><\/ul>"},{"id":"922386-s-3-12","title":"Breast Feeding","mono":"Indomethacin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"922386-s-4","title":"Drug Interactions","sub":[{"id":"922386-s-4-13","title":"Contraindicated","mono":"<ul>Ketorolac (theoretical)<\/ul>"},{"id":"922386-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (probable)<\/li><li>Citalopram (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Desirudin (theoretical)<\/li><li>Digoxin (probable)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (established)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Milnacipran (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nefazodone (probable)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Potassium (probable)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Vasopressin (probable)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"922386-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cilazapril (established)<\/li><li>Clopamide (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Dipyridamole (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Gentamicin (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Warfarin (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},"5":{"id":"922386-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Renal:<\/b>Newborn renal dysfunction (41%), Oliguria (greater than placebo), Serum creatinine raised (greater than placebo)<br\/><b>Serious<\/b><ul><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (3% to 9%)<\/li><li><b>Hematologic:<\/b>Bleeding (significantly greater than placebo), Disseminated intravascular coagulation (significantly greater than placebo)<\/li><li><b>Hepatic:<\/b>Disease of liver<\/li><\/ul>"},"6":{"id":"922386-s-6","title":"Drug Name Info","sub":{"0":{"id":"922386-s-6-17","title":"US Trade Names","mono":"Indocin<br\/>"},"2":{"id":"922386-s-6-19","title":"Class","mono":"<ul><li>Acetic Acid (class)<\/li><li>Analgesic<\/li><li>NSAID<\/li><\/ul>"},"3":{"id":"922386-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"922386-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"922386-s-7","title":"Mechanism Of Action","mono":"Indomethacin is thought to cause closure of a patent ductus arteriosus by inhibiting prostaglandin synthesis. In humans, prostaglandin E1 dilates the ductus arteriosus in newborns with certain congenital heart malformations.<br\/>"},"8":{"id":"922386-s-8","title":"Pharmacokinetics","sub":{"1":{"id":"922386-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: approximately 99%<\/li><li>Brain: crosses blood-brain barrier<\/li><li>Placenta: crosses<\/li><\/ul>"},"2":{"id":"922386-s-8-25","title":"Metabolism","mono":"Metabolized: unknown extent <br\/>"},"3":{"id":"922386-s-8-26","title":"Excretion","mono":"<ul><li>Renal: Unknown extent<\/li><li>Bile: Unknown extent<\/li><\/ul>"},"4":{"id":"922386-s-8-27","title":"Elimination Half Life","mono":"<ul><li>4.5 hours<\/li><li>neonates, 12 to 21 hours (varies inversely with postnatal age and weight)<\/li><\/ul>"}}},"9":{"id":"922386-s-9","title":"Administration","mono":"<b>Intravenous<\/b><br\/><ul><li>dilute with 1 to 2 mL preservative-free 0.9% sterile sodium chloride or sterile water<\/li><li>infuse over 20 to 30 minutes; avoid extravascular injection or leakage, may irritate tissue<\/li><\/ul>"},"10":{"id":"922386-s-10","title":"Monitoring","mono":"<ul><li>closure of the patent ductus arteriosus is indicative of efficacy<\/li><li>renal function; during treatment<\/li><li>serum electrolytes; during treatment<\/li><li>signs of hepatic reaction<\/li><li>presence of blood in stools<\/li><li>intraventricular hemorrhage or signs of bleeding<\/li><\/ul>"},"11":{"id":"922386-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><li><b>Indocin<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><li><b>NovaPlus Indomethacin<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><li><b>PremierPro Rx Indomethacin<\/b><br\/>Intravenous Powder for Solution: 1 MG<br\/><\/li><\/ul>"},"12":{"id":"922386-s-12","title":"Toxicology","sub":[{"id":"922386-s-12-31","title":"Clinical Effects","mono":"<b>INDOMETHACIN<\/b><br\/>USES: Used as an analgesic, antipyretic, and antiinflammatory drug to treat a wide range of pain and inflammatory conditions such as gout, pericarditis, several arthritis conditions, and dysmenorrhea. It is used in neonates for treatment of patent ductus arteriosus. PHARMACOLOGY: Inhibits cyclooxygenases, COX1 and COX2. This results in the decreased synthesis of prostaglandins, thromboxane A2, and decreased pain and inflammation. TOXICOLOGY: GI:  Indomethacin is a direct GI irritant, and the inhibition of prostaglandin synthesis interferes with the maintenance of the GI barrier. Inhibition of thromboxane A2 in platelets prolongs bleeding time and predisposes to GI bleeding. RENAL: Decreases in prostaglandins I2 and E2, which have vasodilatory and natriuretic effects in the kidney that can lead to salt and water retention, and renal failure. MILD TO MODERATE TOXICITY: Nausea, vomiting, and mild abdominal pain may develop. SEVERE TOXICITY: CNS disorientation, mental confusion, and lethargy have been reported. Upper GI bleeding and acute renal failure are also possible. ADVERSE EFFECTS: COMMON: Nausea, vomiting, gastritis, GI ulceration with perforation and hemorrhage, frontal headache, LESS COMMON: Dizziness, vertigo, stupor, hypersensitivity reactions, renal insufficiency, neutropenia, thrombocytopenia, and aplastic anemia. <br\/>"},{"id":"922386-s-12-32","title":"Treatment","mono":"<b>INDOMETHACIN <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Treat GI distress and administer IV fluids. MANAGEMENT OF SEVERE TOXICITY: Administer IV fluids, treat GI distress and monitor for GI bleeding. Patients with severe altered mental status may require intubation.<\/li><li>Decontamination: PREHOSPITAL: No prehospital gastrointestinal decontamination is recommended. HOSPITAL: Administer activated charcoal after large, recent overdose if the patient is alert and can protect the airway. Gastric lavage has no role in the management of indomethacin overdose or toxicity as overdose is not life threatening.<\/li><li>Airway management: Very rarely patients with severe altered mental status may require intubation.<\/li><li>Antidote: None.<\/li><li>Irritation symptom: Antacids, histamine-2 antagonists, sucralfate may be useful with severe irritation.<\/li><li>Monitoring of patient: Monitor for evidence of GI bleeding (eg, guaiac positive stools, decreased hematocrit). Monitor CBC, serum electrolytes and renal function after significant overdose Plasma indomethacin concentrations are not clinically useful or widely available.<\/li><li>Enhanced elimination procedure: Hemodialysis is UNLIKELY to be of benefit due to the high degree of protein binding.<\/li><li>Patient disposition: HOME CRITERIA: Patients with no symptoms or only mild GI distress after inadvertent overdose can be monitored at home. OBSERVATION CRITERIA: Patients with deliberate overdose or more than mild symptoms should be referred to a healthcare facility for evaluation and treatment. If symptoms resolve over 4 to 6 hours, there is no evidence of GI bleeding and laboratory evaluation is normal, the patient discharged home. ADMISSION CRITERIA: Patients with significant systemic signs and symptoms (hematologic disorders such as pancytopenia, metabolic acidosis, altered mental status, renal failure, and significant electrolyte disturbances, or GI hemorrhage) should be admitted and receive appropriate supportive care. CONSULT CRITERIA: Consult a poison center or medical toxicologist for assistance in managing patients with severe signs and symptoms or in whom the diagnosis is unclear.<\/li><\/ul>"},{"id":"922386-s-12-33","title":"Range of Toxicity","mono":"<b>INDOMETHACIN<\/b><br\/>TOXICITY: There are insufficient data to accurately assess the minimal toxic or lethal dose. Severity of intoxication should be based on clinical findings. Doses of 0.2 to 3.75 mg\/kg have resulted in toxic GI symptoms in pre-term infants. Doses up to 175 mg in children and 1500 mg in adults have been tolerated with minor symptoms. Transient renal failure with oliguria, hyponatremia, and hyperkalemia developed in a preterm infant who received 20 mg\/kg of indomethacin intramuscularly. In a  series of 4 infants who inadvertently received a 10 fold overdose (1 mg\/kg), two developed transient increases in BUN or creatinine and three had decreased urine output, but no severe toxicity developed. THERAPEUTIC DOSE: The usual therapeutic dose is 25 to 50 mg 3 to 4 times a day. The maximum recommended adult oral dose is 200 mg daily.<br\/>"}]},"13":{"id":"922386-s-13","title":"Clinical Teaching","mono":"Side effects may include gastrointestinal bleeding, renal failure, hyponatremia, vomiting, abdominal distension, or fluid retention.<br\/>"}}}